Drugs Made In America Acquisition Corp. (DMAAR) Accounts Payables (2024 - 2026)

Drugs Made In America Acquisition (DMAAR) has reported Accounts Payables for 3 consecutive years, with $254412.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accounts Payables rose 25341.2% year-over-year to $254412.0; the trailing twelve-month figure through Jun 2026 stood at $254412.0 (up 25341.2% YoY), and the FY2025 full-year result was $222184.0, up 187.51% from the prior year.
• Accounts Payables grew to $254412.0 in Q2 2026 per DMAAR's latest filing, from $222184.0 in the prior quarter.
• Across five years, Accounts Payables topped out at $254412.0 in Q2 2026 and bottomed at $1000.0 in Q2 2025.
• Historically, Accounts Payables has averaged $127175.2 across 3 years, with a median of $81000.0 in 2025.
• The sharpest annual moves came in 2025 and 2026: Accounts Payables jumped 187.51% in 2025, then soared 25341.2% in 2026.
• Over 3 years, Accounts Payables stood at $77280.0 in 2024, then jumped by 187.51% to $222184.0 in 2025, then gained by 14.51% to $254412.0 in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $254412.0, $222184.0, and $81000.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.